HIV-1 vaccine - GeneCure Biotechnologies
Alternative Names: HIVAX; Replication-defective HIV-1 vaccine (HIVAX™) - GeneCure BiotechnologiesLatest Information Update: 28 Feb 2023
At a glance
- Originator GeneCure
- Developer GeneCure Biotechnologies
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in HIV-1-infections in USA (Parenteral)
- 12 Feb 2021 Phase-I development is ongoing in HIV-1-infections in USA (Parenteral), prior to February 2021 (GeneCure Biotechnologies pipeline, February 2021)
- 01 Apr 2016 Phase-I development is ongoing in USA